U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT06984536) titled 'Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT' on May 03.
Brief Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases. However, donor limitations have restricted the widespread use of allo-HSCT for a long period. The development and success of haploidentical allografts worldwide makes "everyone has a donor" a reality. In the past two decades, researchers have established several haploidentical HSCT (haplo-HSCT) protocols based on different approaches to induce immune tolerance. The representative ap...